BOSTON--(BUSINESS WIRE)--Care Access, a global research company, is enrolling participants at its Santa Clarita, Calif., location to study the effect of an investigational treatment focused on preventing heart attack and stroke in adults with high risk, but no prior history, of major adverse cardiovascular events.
Major atherosclerotic cardiovascular disease (ASCVD) events, such as heart attack and ischemic stroke, are among the leading causes of death in the United States and worldwide. The VICTORION-1 PREVENT phase 3 study by Novartis (randomized, double-blind, placebo-controlled), may offer a way to help prevent life-threatening medical emergencies caused by the buildup of plaque in the arteries.
“Heart attack and stroke impact people from all walks of life within our community and finding ways to prevent these conditions will help us live longer, healthier lives,” said Dr. Sina Tebi, Principal Investigator for Care Access - Santa Clarita. “The clinical trial will enroll patients who are at increased risk, but have no prior history, of major ASCVD events. And participants will be able to stay local, rather than travel into the city.”
The clinical trial will enroll adults 40 to 79 years of age who are at high risk for a first major ASCVD event, based on evidence of plaque in the coronary arteries and other factors that physicians can check for. If you or someone you know is interested or wants to participate in this study, visit managemyheartdisease.com, or contact Care Access at (351) 222-5112 to learn more.
Care Access opened its Santa Clarita location in collaboration with Dr. Tebi and other local healthcare providers. The convenient setting provides residents of Santa Clarita and surrounding communities the option to participate in clinical trials close to home.
About Care Access
Care Access is a global research company helping to accelerate the arrival of new medicines. With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 20 biopharmaceutical companies. In addition to its proven track record of globally top-enrolling sites, Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation. For research sponsors, Care Access offers three core services: (1) global network of research sites, (2) community screenings to expand a study’s reach, and (3) staffing, on-demand physical space expansion, and training services to support all research sites on a study.
To learn more about active studies at Care Access, or how Care Access helps sponsors achieve enrollment and representation goals, visit www.careaccess.com.
